A common form of fatty liver disease may one day be managed, in part, through a precisely chosen fibre supplement that works through the gut. That is the cautious but intriguing message from a new human study examining xylo-oligosaccharides, better known as XOS, in adults with excess weight and early liver fat accumulation.

The research, published in npj Gut and Liver in 2026, is described as the first clinical trial in humans to investigate whether XOS prebiotics can influence liver fat. The study was conducted by researchers from the University of Jyväskylä and the University of Eastern Finland.

Its findings suggest that the supplement may reduce certain harmful gut-derived metabolic byproducts linked to liver fat build-up. Yet the benefit was not uniform. The strongest response appeared in people whose gut microbiota already showed signs of imbalance.

That detail matters. It moves the story beyond a simple “fibre is good” message. The study points towards a more personalised view of nutrition, where the same supplement may help one person more than another because their gut microbes, metabolic state, and stage of liver disease differ.

The condition at the centre of the research is metabolic dysfunction-associated steatotic liver disease, or MASLD. This term refers to liver fat accumulation associated with metabolic risk factors, including overweight, obesity, insulin resistance, abnormal blood lipids, and type 2 diabetes. It is now one of the most common liver disorders worldwide. Among people with excess weight, it is estimated to affect about 75%.

For many, MASLD is silent. There may be no pain. No obvious warning sign. Liver enzymes can be normal, particularly early on. Yet fat accumulation in the liver can become more serious over time. In some people, it may progress to inflammation, scarring, cirrhosis, liver failure, or liver cancer. It is also closely tied to cardiovascular risk, which remains a major concern for this patient group.

Lifestyle change remains the cornerstone of treatment. Weight reduction, healthier eating patterns, more physical activity, better sleep, reduced alcohol intake, and improved control of diabetes or cholesterol can all make a difference.

Still, long-term adherence is difficult. Many people struggle to maintain meaningful weight loss. Others need additional options that are safe, practical, affordable, and easy to combine with standard care.

This is where prebiotics attract attention.

Prebiotics are dietary fibres or fibre-like compounds that human digestive enzymes cannot break down in the upper gut. Instead, they travel to the colon, where they become fuel for selected microbes.

In simple terms, they do not feed the person directly. They feed the person’s microbial ecosystem. XOS is one such prebiotic. It is made of short chains of xylose sugars and has been studied for its potential to shift gut fermentation patterns.

“In people with an imbalanced gut microbiota, XOS appeared to help restore a healthier fermentation balance”

In the Finnish study, 42 adults with overweight consumed 2.8 grams of XOS daily for four months. Liver fat was measured before and after the intervention using magnetic resonance imaging, a method that can assess liver fat non-invasively. The researchers also examined gut microbiota features and metabolic markers to understand who responded, who did not, and why.

The headline finding is not that XOS simply melted away liver fat in everyone. That would be too neat, and not supported by the evidence presented.

The more interesting finding is subtler. XOS reduced levels of certain amino acid-derived metabolites in the gut. These metabolites have previously been associated with liver fat accumulation. In people with an imbalanced gut microbiota, XOS appeared to help restore a healthier fermentation balance.

Gut fermentation can be broadly thought of as the microbial processing of material that reaches the colon. When microbes ferment carbohydrates, such as dietary fibres, they can produce short-chain fatty acids and other compounds often considered beneficial in metabolic health.

When protein fermentation becomes relatively more dominant, certain byproducts may rise. Some of these byproducts are suspected of contributing to metabolic stress, gut barrier dysfunction, or liver fat accumulation, though the exact pathways remain an active area of research.

The liver is especially exposed to these gut-derived substances because blood from the intestine flows directly to it through the portal vein (a blood vessel from the intestine to the liver). This gut-liver connection is not a metaphor. It is anatomy. It helps explain why changes inside the colon may affect the liver, even when the intervention is taken as a dietary supplement.

According to the study report, participants with evidence of greater microbial imbalance at baseline seemed to benefit most. These individuals showed signs suggesting increased protein fermentation relative to carbohydrate fermentation.

After XOS supplementation, their microbial composition shifted in a more favourable direction. In that subgroup, researchers also observed a reduction in visceral fat, the deep abdominal fat that surrounds internal organs and is strongly linked to metabolic disease.

That finding is potentially important because visceral fat is not just a passive energy store. It is metabolically active. It releases inflammatory signals, affects insulin sensitivity, and contributes to the fatty acid flow reaching the liver.

A reduction in visceral fat, if confirmed in larger trials, would strengthen the argument that gut-targeted interventions may influence broader metabolic health.

The study also carries a clear warning against overgeneralisation. XOS did not appear to work equally well in all participants. The effect was weaker, or absent, in people whose blood markers suggested more advanced fatty liver disease.

That may mean prebiotic supplementation is more useful earlier in the disease process, before liver injury and metabolic dysfunction become more entrenched. It may also mean that people with more advanced disease need stronger, broader, or different interventions.

This distinction is vital for patients, clinicians, and supplement companies. A promising signal is not the same as a universal treatment. The study does not show that XOS can replace weight loss, exercise, medical management, or specialist liver care. It does not prove that anyone with fatty liver should immediately begin taking XOS. It does, however, give researchers a stronger reason to study XOS in larger, more targeted groups.

The findings also align with previous animal research. Earlier studies in rats suggested that XOS could reduce fatty liver. Animal results often fail to translate cleanly into humans, so this trial is notable because it tests the idea directly in people. Human biology, real diets, medication use, sleep patterns, physical activity, and diverse microbiomes make clinical research more complicated. They also make it more relevant.

A professional reading of the evidence should be optimistic, not breathless. The sample size was modest, with 42 participants. The intervention lasted four months. The reported benefits depended partly on subgroup characteristics. These are useful early findings, not final answers. Larger randomised studies will be needed to confirm the effect, define the ideal dose, test durability, identify responders, and assess whether improvements in gut metabolites translate into meaningful reductions in liver fat or liver inflammation.

There is another practical question. People do not consume supplements in a vacuum. Their usual diet matters. A person eating a varied diet rich in whole grains, legumes, vegetables, fruit, nuts, and seeds will have a different gut environment from someone eating little fibre and more ultra-processed food. The effect of XOS may depend on the wider food pattern. It may also interact with medications, metabolic health, gut transit time, and existing microbial communities.

That is part of what makes microbiome science exciting and frustrating. The gut microbiota is not a single organ with a fixed setting. It is an ecosystem. It changes with diet, antibiotics, illness, age, geography, sleep, stress, and body weight. Two people can take the same supplement and experience different biological effects. This study supports that view. Baseline microbiota composition appeared to shape the response.

For patients with MASLD, the message should remain grounded. The most evidence-based steps are still weight management where appropriate, regular physical activity, limiting alcohol, reducing excess sugar and refined carbohydrates, improving dietary quality, treating diabetes or high cholesterol, and following medical advice.

Fibre intake is already encouraged as part of many healthy eating patterns. XOS may eventually become one more targeted tool, particularly for people with a specific gut microbial profile. It is not yet a stand-alone solution.

For clinicians, the research adds to a growing case for looking beyond the liver alone. MASLD is a systemic metabolic condition. The gut, adipose tissue, pancreas, muscles, immune system, and liver interact continuously. A gut-targeted therapy that reduces harmful microbial metabolites could fit into a multi-pronged strategy. But clinical use would need better evidence, clear selection criteria, and standardised testing. At present, microbiome profiling is not yet routine care for most people with fatty liver disease.

The study also raises a public health point. Fatty liver disease has expanded alongside obesity, sedentary lifestyles, calorie-dense diets, and metabolic disorders. Drug development is advancing, yet prevention and early intervention remain crucial.

A low-dose prebiotic that improves metabolic signals in selected people would be appealing because it is relatively simple. The challenge is proving that the benefit is real, clinically meaningful, and safe over the long term.

The safety profile of fibre supplements is generally favourable, though gastrointestinal symptoms such as bloating, gas, or altered bowel habits can occur. People with medical conditions, complex digestive disorders, or those taking multiple medicines should seek professional guidance before adding supplements. More is not always better. Dose, timing, formulation, and personal tolerance all matter.

The researchers behind the work suggest that XOS may help restore gut fermentation balance, reduce harmful metabolites, and support liver health when used in the right target group. They also stress that larger, more focused studies are needed.

That balance is the real news. Not a miracle fibre. Not a cure. A signal.

A small daily dose of XOS, taken for four months, appeared to shift gut metabolism in a direction that may be favourable for the liver, especially in people with microbial imbalance and early steatosis. The response depended on biology already present before treatment began.

In future, this could help shape personalised nutrition for MASLD, where gut microbiota patterns guide who receives which dietary intervention.

For now, the study offers a useful glimpse of where liver medicine may be heading. The next generation of fatty liver care may not focus only on calories, scales, or liver scans. It may also look closely at the microbial chemistry happening quietly inside the gut. That hidden chemistry could help explain why some people improve, why others do not, and how simple nutritional tools might be used with greater precision.